HK1215857A1 - 与th2抑制相关的诊断和治疗 - Google Patents

与th2抑制相关的诊断和治疗 Download PDF

Info

Publication number
HK1215857A1
HK1215857A1 HK16103827.5A HK16103827A HK1215857A1 HK 1215857 A1 HK1215857 A1 HK 1215857A1 HK 16103827 A HK16103827 A HK 16103827A HK 1215857 A1 HK1215857 A1 HK 1215857A1
Authority
HK
Hong Kong
Prior art keywords
antibody
patient
asthma
periostin
seq
Prior art date
Application number
HK16103827.5A
Other languages
English (en)
Chinese (zh)
Inventor
Joseph R. Arron
Richard W. Erickson
Michelle Freemer
Meredith Hazen
Guiquan Jia
John G. MATTHEWS
Wendy Putnam
Heleen Scheerens
Yanan Zheng
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of HK1215857A1 publication Critical patent/HK1215857A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16103827.5A 2010-12-16 2016-04-05 与th2抑制相关的诊断和治疗 HK1215857A1 (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US45976010P 2010-12-16 2010-12-16
US61/459,760 2010-12-16
US201161465425P 2011-03-18 2011-03-18
US61/465,425 2011-03-18
US201161484650P 2011-05-10 2011-05-10
US61/484,650 2011-05-10
US201161574485P 2011-08-02 2011-08-02
US61/574,485 2011-08-02
US201161557295P 2011-11-08 2011-11-08
US61/557,295 2011-11-08

Publications (1)

Publication Number Publication Date
HK1215857A1 true HK1215857A1 (zh) 2016-09-23

Family

ID=46234723

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103827.5A HK1215857A1 (zh) 2010-12-16 2016-04-05 与th2抑制相关的诊断和治疗

Country Status (19)

Country Link
US (4) US20120156194A1 (enExample)
EP (2) EP3447491A3 (enExample)
JP (4) JP6005657B2 (enExample)
KR (4) KR101923282B1 (enExample)
CN (4) CN105169390A (enExample)
AR (1) AR084342A1 (enExample)
AU (1) AU2011343570B2 (enExample)
BR (2) BR112013013460A8 (enExample)
CA (2) CA3040095C (enExample)
HK (1) HK1215857A1 (enExample)
IL (2) IL226821B (enExample)
MX (2) MX352789B (enExample)
MY (1) MY188365A (enExample)
NZ (2) NZ609493A (enExample)
RU (2) RU2578468C2 (enExample)
SG (3) SG10201401746TA (enExample)
TW (4) TW201732294A (enExample)
WO (1) WO2012083132A2 (enExample)
ZA (1) ZA201302979B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
CN102232113A (zh) * 2008-03-31 2011-11-02 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
EP3447491A3 (en) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
EP3725892A1 (en) * 2012-03-27 2020-10-21 F. Hoffmann-La Roche AG Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
MX2015012326A (es) 2013-03-15 2016-03-08 Genentech Inc Anticuerpos anti-crth2 y su uso.
WO2014151648A1 (en) * 2013-03-15 2014-09-25 Coronado Biosciences, Inc. Treatment of autoimmune disease using helminthic parasites
PL3033101T3 (pl) * 2013-08-12 2019-06-28 Astrazeneca Ab Sposoby zmniejszania częstości zaostrzeń astmy przy użyciu benralizumabu
PL3033104T3 (pl) * 2013-08-12 2019-09-30 Astrazeneca Ab Sposoby zwiększania natężonej objętości wydechowej u astmatyków za pomocą benralizumabu
CA2918050C (en) * 2013-08-12 2023-10-03 Medimmune, Llc Methods for improving asthma symptoms using benralizumab
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
US10553320B1 (en) * 2013-09-19 2020-02-04 Cerner Innovation, Inc. Personal analysis and chronotherapy
JP6250351B2 (ja) * 2013-09-30 2017-12-20 シスメックス株式会社 好酸球性気道炎症に関する情報の取得方法およびそのような情報を取得するためのマーカー
SG10201807318RA (en) * 2013-10-15 2018-09-27 Astrazeneca Ab Methods for treating chronic obstructive pulmonary disease using benralizumab
BR112016008694A2 (pt) * 2013-10-23 2017-10-03 Genentech Inc Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
WO2015106080A2 (en) 2014-01-10 2015-07-16 Anaptysbio, Inc. Antibodies directed against interleukin-33 (il-33)
EP3099323A4 (en) 2014-01-27 2017-10-04 Medlmmune, LLC Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung
BR112016017901A2 (pt) 2014-02-07 2017-10-10 Abbott Lab ensaio inovador para detectar periostina humana
WO2015126750A1 (en) * 2014-02-19 2015-08-27 Array Biopharma Inc. BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO TREATMENT WITH A CRTh2 INHIBITOR
MX2016010729A (es) 2014-02-21 2016-10-26 Genentech Inc Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
KR20160138095A (ko) 2014-04-11 2016-12-02 노파르티스 아게 Il-13 길항제를 사용하여 천식을 선택적으로 치료하는 방법
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
MA40164A (fr) * 2014-06-27 2017-05-03 Sanofi Sa Anticorps bispécifiques anti-il4-il13
KR102495432B1 (ko) 2014-09-08 2023-02-03 세파론 엘엘씨 중등증 내지 중증의 호산성 천식을 치료하기 위한 레슬리주맙의 용도
JP7095990B2 (ja) 2014-09-18 2022-07-05 シーダーズ－サイナイ メディカル センター 線維症を治療するための組成物及び方法
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
HK1243141A1 (zh) 2014-12-23 2018-07-06 豪夫迈．罗氏有限公司 用於治疗和诊断化学疗法抗性癌症的组合物和方法
AU2016205188A1 (en) 2015-01-09 2017-06-22 Medimmune, Llc Assay to detect human DPP-4
CA2977285A1 (en) * 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases
HK1255922A1 (zh) 2015-11-04 2019-09-06 Astrazeneca Ab 二肽基肽酶-4和骨膜素作为嗜酸性粒细胞疾病中嗜酸性粒细胞靶向治疗药物临床反应的预测因子
CA3017582A1 (en) * 2016-02-17 2017-08-24 Icahn School Of Medicine At Mount Sinai Nasal biomarkers of asthma
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
AU2017257330A1 (en) 2016-04-27 2018-10-18 Pfizer Inc. Anti-IL-33 antibodies, compositions, methods and uses thereof
HRP20231015T1 (hr) * 2016-09-23 2023-12-08 F. Hoffmann-La Roche Ag Upotreba antagonista il-13 u liječenju atopičnog dermatitisa
TWI778018B (zh) 2017-02-10 2022-09-21 美商建南德克公司 抗類胰蛋白酶抗體、其組合物及其用途
WO2019157358A1 (en) 2018-02-09 2019-08-15 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
WO2019183131A1 (en) 2018-03-19 2019-09-26 Bioventures, Llc Periostin antibodies and methods of using the same
CN108977511A (zh) * 2018-07-03 2018-12-11 张罗 检测鼻腔脱落细胞中cst1基因表达量的方法及应用
CN111415728A (zh) * 2019-11-25 2020-07-14 刘雷 基于cnn和gan的ct图像数据自动分类方法及设备
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof
CN113501878B (zh) * 2021-02-03 2022-12-02 北京智仁美博生物科技有限公司 针对人tslp的多种抗体及其用途
TWI859566B (zh) * 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
JP2023140319A (ja) 2022-03-22 2023-10-04 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン
CU20250005A7 (es) * 2022-06-17 2025-11-05 Apogee Biologics Inc Anticuerpos que se unen a interleuquina 13

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578349A (en) 1982-04-08 1986-03-25 Abbott Laboratories Immunoassay for carcinoembryonic antigen (CEA)
US4818709A (en) 1983-01-21 1989-04-04 Primus Frederick J CEA-family antigens, Anti-CEA antibodies and CEA immunoassay
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5274087A (en) 1986-08-13 1993-12-28 Molecular Diagnostics, Inc. cDNA coding for carcinoembryonic antigen (CEA)
US5122599A (en) 1986-08-13 1992-06-16 Molecular Diagnostics, Inc. CDNAS coding for members of the carcinoembryonic antigen family
ES2059330T3 (es) 1986-08-13 1994-11-16 Miles Inc Un cdna codificador de antigeno carcinoembrionico.
US5231009A (en) 1986-08-13 1993-07-27 Molecular Diagnostics, Inc. Cdnas coding for members of the carcinoembryonic antigen family
US6013772A (en) 1986-08-13 2000-01-11 Bayer Corporation Antibody preparations specifically binding to unique determinants of CEA antigens or fragments thereof and use of the antibody preparations in immunoassays
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
GB8800078D0 (en) 1988-01-05 1988-02-10 Ciba Geigy Ag Novel antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
JP3951062B2 (ja) 1991-09-19 2007-08-01 ジェネンテック・インコーポレーテッド 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP1997894B1 (en) 1992-02-06 2011-03-30 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
JPH05268982A (ja) 1992-03-27 1993-10-19 Hoechst Japan Ltd 骨形成作用を有する新規な蛋白質およびその製造法
WO1994004680A1 (en) 1992-08-21 1994-03-03 Schering Corporation Human interleukin-13
US5596072A (en) 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
PT752248E (pt) 1992-11-13 2001-01-31 Idec Pharma Corp Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
WO1995011923A1 (en) 1993-10-29 1995-05-04 Dana-Farber Cancer Institute, Inc. A novel tumor marker and novel method of isolating same
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1996010911A1 (en) 1994-10-05 1996-04-18 Immunex Corporation Cytokine designated lerk-6
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6518061B1 (en) 1995-03-15 2003-02-11 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6911530B1 (en) 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
DE19614062A1 (de) 1996-04-09 1997-10-16 Bayer Ag Verfahren zur kontinuierlichen Herstellung von Diarylcarbonaten
US20060073133A1 (en) * 1997-04-02 2006-04-06 Kikly Kristine K Sialoadhesin factor-3 antibodies
US6518063B1 (en) 1997-05-29 2003-02-11 Board Of Regents, The University Of Texas System Osf2/Cbfa1 nucleic acids and methods of use therefor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
JP2002506353A (ja) 1997-06-24 2002-02-26 ジェネンテック・インコーポレーテッド ガラクトシル化糖タンパク質の方法及び組成物
JP2002513295A (ja) 1997-07-08 2002-05-08 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド １２３種類のヒト分泌タンパク質
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
WO1999022764A1 (en) 1997-10-31 1999-05-14 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US6482403B1 (en) 1998-05-29 2002-11-19 Heska Corporation Caniney IL-13 immunoregulatory proteins and uses thereof
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000044407A2 (en) 1999-02-01 2000-08-03 Amgen Canada Materials and methods to inhibit hodgkin and reed sternberg cell growth
WO2000061739A1 (fr) 1999-04-09 2000-10-19 Kyowa Hakko Kogyo Co., Ltd. Methode de regulation de l'activite d'une molecule immunologiquement fonctionnelle
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
EP1222292B1 (en) 1999-10-04 2005-08-31 Medicago Inc. Method for regulating transcription of foreign genes in the presence of nitrogen
US7504256B1 (en) 1999-10-19 2009-03-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing polypeptide
EP1240319A1 (en) 1999-12-15 2002-09-18 Genentech, Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
DK1242438T3 (da) 1999-12-29 2007-02-12 Immunogen Inc Cytotoksiske midler omfattende modificerede doxorubiciner og daunorubiciner og deres terapeutiske anvendelse
US6989145B2 (en) 2000-03-03 2006-01-24 Kyowa Hakko Kogyo Co., Ltd. Recombinant antibody and antibody fragment
US7439064B2 (en) 2000-03-09 2008-10-21 Wicell Research Institute, Inc. Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
AU2001284483B2 (en) 2000-09-08 2006-08-10 Asubio Pharma Co., Ltd. Remedies for heart failure
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
MXPA03002974A (es) 2000-10-06 2004-05-05 Kyowa Hakko Kogyo Kk Celulas que producen composiciones de anticuerpo.
AU2002210918B2 (en) 2000-10-20 2006-03-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
ES2311558T3 (es) 2000-10-20 2009-02-16 Genetics Institute, Inc. Uso de inhibidores de la il-13 para el tratamiento de tumores.
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR100857943B1 (ko) 2000-11-30 2008-09-09 메다렉스, 인코포레이티드 인간 항체의 제조를 위한 형질전환 트랜스염색체 설치류
JP4155561B2 (ja) * 2000-12-26 2008-09-24 国立大学法人佐賀大学 アレルギー性疾患検査方法
US6596240B2 (en) 2001-01-12 2003-07-22 Porex Corporation Pipette tip for easy mounting and ejecting from a pipette
US20050107595A1 (en) 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR100788092B1 (ko) 2001-06-20 2007-12-21 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
CA2838062C (en) 2001-08-03 2015-12-22 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
WO2003016471A2 (en) 2001-08-13 2003-02-27 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
CN100430420C (zh) 2001-08-31 2008-11-05 协和发酵工业株式会社 人cdr-移植抗体及其抗体片段
US7384736B2 (en) 2001-09-06 2008-06-10 Decode Genetics Ehf. Methods for predicting drug sensitivity in patients afflicted with an inflammatory disease
GB0123951D0 (en) * 2001-10-05 2001-11-28 Glaxo Group Ltd Therapies for treating respiratory diseases
NZ532526A (en) 2001-10-25 2007-01-26 Genentech Inc Compositions comprising a glycoprotein having a Fc region
EP1578912A4 (en) 2001-10-26 2007-12-26 Centocor Inc IL-13 MUTEIN PROTEINS, ANTIBODIES, COMPOSITIONS, METHODS AND USES
WO2003038055A2 (en) 2001-10-31 2003-05-08 Mds Proteomics, Inc. Proteins involved in regulation of adipocytes and uses related thereto
AU2002367732A1 (en) 2001-10-31 2003-09-09 Children's Hospital Medical Center Method for diagnosis and treatment of rheumatoid arthritis
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
WO2003086451A1 (en) 2002-04-05 2003-10-23 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
DE20205500U1 (de) 2002-04-09 2002-07-11 Hurth, Ursula, 66450 Bexbach Tampon
MXPA04009924A (es) 2002-04-09 2005-07-01 Kyowa Hakko Kogyo Kk Celulas de genoma modificado.
US20040259150A1 (en) 2002-04-09 2004-12-23 Kyowa Hakko Kogyo Co., Ltd. Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
SE522615C2 (sv) 2002-07-09 2004-02-24 Martin Tiberg Med Tiberg Techn En metod och ett system för biometrisk identifiering eller verifiering.
JP2004121218A (ja) 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
AR042485A1 (es) 2002-12-16 2005-06-22 Genentech Inc Anticuerpo humanizado que se une al cd20 humano
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
DE10304350B3 (de) 2003-02-03 2004-06-09 Sabeu Kunststoffwerk Northeim Gmbh Behälterverschluß
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 ｉｌ­９ 항체 및 그의 용도
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
JP4703567B2 (ja) 2003-05-23 2011-06-15 ジェネンテック， インコーポレイテッド 膠細胞起源の腫瘍の診断と治療のための組成物と方法
KR20060013425A (ko) 2003-05-29 2006-02-09 밀레니엄 파머슈티컬스 인코퍼레이티드 유방암의 확인, 평가, 예방 및 요법에 대한 조성물, 키트및 방법
EP1633892A4 (en) 2003-06-10 2007-10-24 Univ Boston DETECTION METHODS FOR LUNG DISEASES
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
WO2005019471A2 (en) 2003-08-13 2005-03-03 Temple University Of The Commonwealth System Of Higher Education Periostin-like factor: compositions and methods for making and using the same
US20050053549A1 (en) 2003-09-10 2005-03-10 Aperon Biosystems Corp. Method for treating airway disorders
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
AU2004280065A1 (en) 2003-10-09 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
TR201809892T4 (tr) 2003-11-05 2018-07-23 Roche Glycart Ag Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller.
CN104998273A (zh) 2003-11-06 2015-10-28 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
DK3718564T3 (da) 2003-12-23 2023-11-06 Genentech Inc Nye anti-IL-13-antistoffer og anvendelser
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
CA2885854C (en) 2004-04-13 2017-02-21 F. Hoffmann-La Roche Ag Anti-p-selectin antibodies
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
KR100635540B1 (ko) 2004-10-12 2006-10-18 경북대학교 산학협력단 신규한 염증성 질환의 예방 또는 치료용 약학적 조성물
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008520684A (ja) * 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
EP1957530A2 (en) 2005-10-21 2008-08-20 Novartis AG Human antibodies against il13 and therapeutic uses
ES2577292T3 (es) 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2006334029B2 (en) 2005-12-28 2013-01-31 Osaka University An antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
US8017119B2 (en) * 2005-12-28 2011-09-13 Daiichi Sankyo Company, Ltd. Antibody against periostin, and a pharmaceutical composition comprising it for preventing or treating a disease in which periostin is involved
JP2009525267A (ja) 2006-01-11 2009-07-09 アエロヴァンス インコーポレイティッド ヒトおよび非ヒト霊長類において喘息を処置するための方法および組成物
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
AU2007218158A1 (en) 2006-02-22 2007-08-30 Philogen Spa Vascular tumor markers
EP2016101A2 (en) 2006-05-09 2009-01-21 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20070275925A1 (en) 2006-05-17 2007-11-29 Regents Of The University Of California Asthma diagnosis and therapy
WO2008016356A2 (en) 2006-08-02 2008-02-07 Genizon Biosciences Genemap of the human genes associated with psoriasis
PL2059533T3 (pl) 2006-08-30 2013-04-30 Genentech Inc Przeciwciała wieloswoiste
KR101625961B1 (ko) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
CA2683109A1 (en) * 2006-10-11 2008-04-17 Fusion Antibodies Limited Combination therapy
JP4369468B2 (ja) 2006-12-15 2009-11-18 日本分光株式会社 不可逆反応測定方法
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TW200837080A (en) 2007-01-09 2008-09-16 Wyeth Corp Anti-IL-13 antibody formulations and uses thereof
RS53402B (sr) 2007-03-22 2014-10-31 Genentech, Inc. Vezivanje apoptotskih anti-ige antitela za membranski ige
RU2009140134A (ru) * 2007-04-23 2011-05-27 Вайет (Us) Способы и композиции для лечения и мониторинга лечения связанных с ил-13 нарушений
US20100086554A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
WO2008140455A1 (en) 2007-05-15 2008-11-20 Tanox, Inc. Treatment of radiation and chemo-therapy induced fibrosis using novel anti-il 13 monoclonal antibodies
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
CA2690888C (en) 2007-06-27 2016-02-09 Asubio Pharma Co., Ltd. Cancer therapeutic composition comprising antibody against peptide encoded by exon-17 site of periostin
WO2009009775A1 (en) 2007-07-11 2009-01-15 Aerovance, Inc. Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation
AU2009204501B2 (en) 2008-01-07 2015-02-12 Amgen Inc. Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
CN102232113A (zh) * 2008-03-31 2011-11-02 健泰科生物技术公司 用于治疗和诊断哮喘的组合物和方法
WO2009148184A1 (ja) * 2008-06-05 2009-12-10 国立大学法人佐賀大学 特発性間質性肺炎の検出方法
WO2010007701A1 (ja) 2008-07-18 2010-01-21 国立大学法人東京工業大学 心筋壊死を伴う疾患の治療薬及び検査薬
EP2329025A4 (en) * 2008-09-08 2012-04-25 Ottawa Hospital Res Inst PERIOSTIN-INDUCED PANCAKE RENEWAL
JP5522717B2 (ja) * 2008-09-19 2014-06-18 国立大学法人佐賀大学 アトピー性皮膚炎の検出方法および予防・治療剤のスクリーニング方法
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
FR2946349B1 (fr) * 2009-06-03 2013-10-04 Synarc Sas Sequences, anticorps, procedes et necessaires pour la detection et le dosage in vitro de la periostine, en vue du diagnostic du suivi ou du pronostic de pathologies ou de phenomenes biologiques impliquant la periostine
EP3447491A3 (en) * 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnosis and treatments relating to th2 inhibition
EP2754672B1 (en) * 2011-09-06 2019-02-27 Shino-Test Corporation Antibody capable of binding to specific region of periostin, and method of measuring periostin using the same

Also Published As

Publication number Publication date
EP3447491A2 (en) 2019-02-27
RU2578468C2 (ru) 2016-03-27
US20120156194A1 (en) 2012-06-21
KR101615420B1 (ko) 2016-04-26
CA2817380A1 (en) 2012-06-21
KR101616260B1 (ko) 2016-04-29
RU2015139698A3 (enExample) 2019-05-07
WO2012083132A3 (en) 2012-08-30
RU2737245C2 (ru) 2020-11-26
SG10201401763SA (en) 2014-09-26
IL226821B (en) 2020-09-30
CN103688171A (zh) 2014-03-26
IL262278A (en) 2018-11-29
TW201250244A (en) 2012-12-16
EP2652498B1 (en) 2018-04-18
RU2015139698A (ru) 2018-12-26
MX371228B (es) 2020-01-10
JP6297526B2 (ja) 2018-03-20
TWI666447B (zh) 2019-07-21
AU2011343570B2 (en) 2016-11-03
MX352789B (es) 2017-12-08
BR112013013460A8 (pt) 2019-02-12
SG10201401746TA (en) 2014-10-30
US20190120854A1 (en) 2019-04-25
US9995755B2 (en) 2018-06-12
TW201732294A (zh) 2017-09-16
KR101923282B1 (ko) 2018-11-28
IL262278B (en) 2020-11-30
KR101615474B1 (ko) 2016-04-25
CA2817380C (en) 2019-06-04
CA3040095A1 (en) 2012-06-21
MX2013006712A (es) 2014-02-03
EP3447491A3 (en) 2019-06-05
JP2016041689A (ja) 2016-03-31
CN105175542A (zh) 2015-12-23
EP2652498A4 (en) 2014-05-21
AR084342A1 (es) 2013-05-08
NZ713202A (en) 2017-12-22
JP2015091812A (ja) 2015-05-14
CN105169390A (zh) 2015-12-23
BR112013013460A2 (pt) 2017-09-05
CN103688171B (zh) 2017-10-24
EP2652498A2 (en) 2013-10-23
KR20130082508A (ko) 2013-07-19
TWI708944B (zh) 2020-11-01
TWI732259B (zh) 2021-07-01
US20140044702A1 (en) 2014-02-13
MY188365A (en) 2021-12-06
HK1215711A1 (zh) 2016-09-09
JP2014506321A (ja) 2014-03-13
SG190885A1 (en) 2013-07-31
AU2011343570A1 (en) 2013-05-02
US11226341B2 (en) 2022-01-18
JP2018009998A (ja) 2018-01-18
CN112168962A (zh) 2021-01-05
US9684000B2 (en) 2017-06-20
JP6005657B2 (ja) 2016-10-12
WO2012083132A2 (en) 2012-06-21
RU2013132733A (ru) 2015-01-27
US20140044645A1 (en) 2014-02-13
CA3040095C (en) 2021-09-07
CN105175542B (zh) 2018-12-18
KR20150008919A (ko) 2015-01-23
TW201945734A (zh) 2019-12-01
KR20150014985A (ko) 2015-02-09
NZ609493A (en) 2015-11-27
BR122020012255B1 (pt) 2022-08-09
ZA201302979B (en) 2019-09-25
JP6502069B2 (ja) 2019-04-17
KR20160052758A (ko) 2016-05-12
TW201937166A (zh) 2019-09-16

Similar Documents

Publication Publication Date Title
US11226341B2 (en) Method of treating asthma using an IL-13 antibody
AU2013204902A1 (en) Diagnosis and treatments relating to TH2 inhibition
HK40044503A (en) Diagnosis and treatments relating to th2 inhibition
HK1196159A (en) Diagnosis and treatments relating to th2 inhibition
HK1196159B (en) Diagnosis and treatments relating to th2 inhibition
HK1215711B (zh) 与th2抑制相关的诊断和治疗